Market Herald logo


Be the first with the news that moves the market

ResApp has submitted an application to the US Food and Drug Administration for the classification of its mobile software ResAppDx-US.

Created at the University of Queensland, this software can be used to diagnose and measure the severity of a wide range of chronic and acute diseases.

All patients need to do is cough into the phone and the algorithms use the sound to diagnose and measure the severity of the conditions without the need for additional hardware.

These sounds are then matched up and compared to those with the disease located in the database.

ResAppDx-US is intended to be used by clinicians to aid in the diagnosis of primary respiratory tract disease, lower respiratory tract disease, and asthma.

With respiratory diseases causing the majority of healthcare concerns in children, this app has the potential to improve diagnosis accuracy, improve testings and shorten treatment time.

CEO Tony Keating is excited to launch this product and hopes many people can benefit from it.

“We are now entering a new and exciting phase in ResApp’s evolution as we prepare for the commercial launch of ResAppDx-US,” he said.

However, this is not currently available in the United States as a request for De Novo is pending review.

Please find announcement attached:

RAP by the numbers
More From The Market Herald
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) doses first patient in CHECKvacc clinical trial

Imugene (IMU) has announced that cancer and research centre, City of Hope, has dosed the first patient in the phase one clinical trial
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.69) from US family office fund, Quincy Street Capital.
Incannex Healthcare (ASX:IHL)

" Incannex Healthcare (ASX:IHL) engages Procaps to manufacture sleep apnoea treatment

Incannex Healthcare (IHL) has engaged a company to manufacture its soft-gel capsules in preparation for upcoming clinical trials.

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).